Qnasl patents expiration

QNASL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7780038 TEVA BRANDED PHARM Dispensing apparatus with dosage counter
Jan, 2027

(3 years from now)

US10188811 TEVA BRANDED PHARM Nasal spray device
Oct, 2031

(8 years from now)

Qnasl is owned by Teva Branded Pharm.

Qnasl contains Beclomethasone Dipropionate.

Qnasl has a total of 2 drug patents out of which 0 drug patents have expired.

Qnasl was authorised for market use on 23 March, 2012.

Qnasl is available in aerosol, metered;nasal dosage forms.

The generics of Qnasl are possible to be released after 21 October, 2031.

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 23 March, 2012

Treatment: NA


More Information on Dosage

QNASL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic